AstraZeneca reckons it can add $500 million merger of synergies, most of which are cost savings. Alexion shareholders are estimated to own about 15% of the merged company upon completion. Granted, Alexion Pharmaceuticals isn’t the industry’s most exciting acquisition target, but this deal will most likely work out well for investors in the long run. In a chaotic year where healthcare has dominated the headlines, AstraZeneca surprised the market by announcing that they had agreed to acquire Alexion Pharmaceuticals Inc. (Alexion) for $39 billion USD. “Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases. And at $39bn the transaction was not only 2020’s sole mega-merger, it also went a long way to saving the year from being distinctly pedestrian in terms of deal size. The numbers work out AstraZeneca finished September with about $8 billion in cash and $22 billion in debt. Late last week, AstraZeneca said that it would acquire Alexion Pharmaceuticals - a company best known for its Soliris and Ultomiris drugs - in a … 7 hours ago BTC/USD: Bitcoin Price Targets Critical Resistance at 58,200 9 hours ago Clearance of 3950/3951 Could Send the S&P 500 Towards 4070/4075 – Credit Suisse 10 hours ago Dow Jones Hits New Record High as Inflation … AstraZeneca noted that it intends to establish its U.S. headquarters for rare diseases in Boston, Mass., … Freshfields and Wachtell act on USD 39 billion AstraZeneca-Alexion merger. Alexion shareholders will be paid $60 USD per share in cash, as well as 2.1243 AstraZeneca American Depositary Shares (ADSs), amounting to a total consideration […] With the Alexion deal, it will also now be trying to orchestrate a giant corporate merger at the same time. The acquisition will be undertaken through a US statutory merger in which Alexion shareholders will receive $60 in cash and 2.1243 new AstraZeneca ADSs listed on the Nasdaq exchange for each of their Alexion shares. Published by: Sandy Bhadare at 14 Dec 2020 British-Swedish pharmaceutical and biopharmaceutical giant AstraZeneca has entered into a definitive agreement to acquire American pharmaceutical company Alexion Pharmaceuticals for USD 39 billion. AstraZeneca will be liable to pay $1.4 billion in break fee to Alexion under specific circumstances which include a change of AstraZeneca’s board recommendation. AstraZeneca (), one of the frontrunners in the drugs industry’s search for a COVID-19 vaccine, announced on Saturday that it will acquire US drugmaker Alexion for $39bn (£29.5bn).Under the terms of the transaction, the FTSE 100 firm said that Alexion shareholders will get $60 in cash and about 2.1 from AstraZeneca’s US-listed shares for each Alexion share they own. Per the terms of the deal, Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) for each Alexion share. AstraZeneca's facilities in Sodertalje, Sweden. The companies said they expected the acquisition to close in the third quarter of next year. “AstraZeneca intends to build on its geographical footprint and extensive emerging markets presence to accelerate the worldwide expansion of Alexion’s portfolio,” the companies said. AstraZeneca will pay $39 billion to acquire Alexion in an immunology-driven deal that drives the British drugmaker closer to CEO Pascal Soriot's $40 billion revenue goal by 2023. ALEXION MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF ALEXION PHARMACEUTICALS, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – ALXN. December 12, 2020. Here's why it dropped . The merger agreement, which will see Alexion shareholders receive $60 in cash and 2.1 AstraZeneca shares for every Alexion share they own – equating to an overall price of about $175 per share – has yet to be approved by regulators, though it is expected to close during the third quarter of 2021. AstraZeneca-Alexion Merger. AstraZeneca said Alexion will give it a foothold in the lucrative field of rare-disease drugs and help fuel revenue and cash flow in the coming years. This cash and stock merger … AstraZeneca Buying Alexion for $39 Billion A major drug merger seizes headlines as early vaccinations begin in the U.S. By John Divine, Senior Investing Reporter Dec. 14, 2020. Per the terms of the deal, Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) for each Alexion share. ... AstraZeneca to acquire Alexion for $39bn. AstraZeneca will pay around $175 per share for Alexion, through a combination of cash and shares, representing a near 45% premium to the group's Friday closing price and valuing the … Commenting on the proposed merger between Alexion (NASDAQ:ALXN) and AstraZeneca (NASDAQ:AZN), Piper Sandler highlights the ‘durability’ of large … January 24, 2021 / No Comments / Healthcare & Pharmaceuticals, News. Upon completion of merger, Alexion shareholders will own approximately 15% of combined company. AstraZeneca’s $39 billion splurge to acquire Alexion Pharmaceuticals looks like a winner--as long as it can hang on at that price tag. According to the terms of the deal, Alexion will be liable to pay $1.2 billion in break fee to AstraZeneca in certain situations which include completion of an alternative merger or a change of Alexion’s board recommendation. On the 13th of December AstraZeneca announced the acquisition of rare disease specialist Alexion. 3 Reasons AstraZeneca's Merger With Alexion Will Work for Investors 1. On 27 December 2020, the AstraZeneca chief Pascal Soriot said that they have “figured out the winning formula” with their two-dose system with the Oxford University’s COVID-19 vaccine. Forum Merger III to merge with Electric Last Mile in a $1.4bn deal. AstraZeneca offered $39 billion for Alexion in a combination of cash and stock, although a lack of enthusiasm for the deal has pressed AstraZeneca shares lower since the announcement. AstraZeneca share price is down by more than 5% today as traders react to the company's planned acquisition of Alexion. Ultomiris is a hit If biology isn't really your thing, an overactive complement system might not sound like a... 2. And more recently, Bloomberg reported that AstraZeneca had approached Gilead, the Californian biotech known for its work in antivirals, including the COVID-19 therapy Veklury, about a potential merger. Biotech to be ‘Extremely Active’ in 2020 Mergers and Acquisitions; The acquisition is expected to close in Q3 of 2021. Long-term results could be rewarding: investors should give this the benefit of the doubt . This cash and stock merger … The deal, worth 15 billion USD, capped a busy year for AstraZeneca during which the development of its vaccine with Oxford University had temporarily made it the most valuable FTSE 100 company. AstraZeneca/Alexion: the odd couple. Breaking News. AstraZeneca, a science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, agreed to acquire Alexion, a global biopharmaceutical company focused on development and commercialisation of life-changing … Post merger, the companies indicated that AstraZeneca plans to work closely with Alexion's R&D team to build upon and expand Alexion's current pipeline of 11 molecules, which have been studied in greater than 20 clinical development programs across a wide spectrum of rare diseases. The company agreed to buy Alexion Pharmaceuticals Inc. for $39 billion in cash and shares on Dec. 12, 2020. After suffering years of takeover speculation Alexion finally got taken off the board by Astrazeneca. With the Alexion deal, it will also now be trying to orchestrate a giant corporate merger at the same time. Alexion has about 3,000 employees, while AstraZeneca has about 70,000.